Hangzhou Alltest Biotech Co. Ltd. A (688606) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hangzhou Alltest Biotech Co. Ltd. A (688606) has a cash flow conversion efficiency ratio of 0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥55.21 Million ≈ $8.08 Million USD) by net assets (CN¥3.90 Billion ≈ $570.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View Hangzhou Alltest Biotech Co. Ltd. A stock price for real-time trading data and today's change.
Hangzhou Alltest Biotech Co. Ltd. A - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Hangzhou Alltest Biotech Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Hangzhou Alltest Biotech Co. Ltd. A market cap and net worth for the company's overall valuation and market capitalisation.
Hangzhou Alltest Biotech Co. Ltd. A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hangzhou Alltest Biotech Co. Ltd. A ranked by their cash flow conversion efficiency. Also see balance sheet size of Hangzhou Alltest Biotech Co. Ltd. A for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Midi Utama Indonesia Tbk
JK:MIDI
|
0.038x |
|
Sichuan Xichang Electric Power Co Ltd
SHG:600505
|
0.101x |
|
MOIL Limited
NSE:MOIL
|
0.050x |
|
TELUS International
TO:TIXT
|
0.078x |
|
PRINC.PR.EQ.HLDGS EO-001
F:PEYA
|
N/A |
|
Zhejiang Tengen Electrics Co Ltd
SHG:605066
|
N/A |
|
Diversified Royalty Corp
TO:DIV
|
0.027x |
|
Ningbo Shenglong Automotive Powertrain System Co Ltd
SHG:603178
|
0.065x |
Annual Cash Flow Conversion Efficiency for Hangzhou Alltest Biotech Co. Ltd. A (2016–2025)
The table below shows the annual cash flow conversion efficiency of Hangzhou Alltest Biotech Co. Ltd. A from 2016 to 2025. Review financial flexibility index of Hangzhou Alltest Biotech Co. Ltd. A to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥3.95 Billion ≈ $577.47 Million |
CN¥206.59 Million ≈ $30.23 Million |
0.052x | -38.30% |
| 2024-12-31 | CN¥3.88 Billion ≈ $568.27 Million |
CN¥329.52 Million ≈ $48.22 Million |
0.085x | +1212.89% |
| 2023-12-31 | CN¥3.83 Billion ≈ $560.68 Million |
CN¥24.76 Million ≈ $3.62 Million |
0.006x | -98.02% |
| 2022-12-31 | CN¥4.17 Billion ≈ $610.34 Million |
CN¥1.36 Billion ≈ $199.11 Million |
0.326x | +15.60% |
| 2021-12-31 | CN¥3.27 Billion ≈ $479.04 Million |
CN¥923.87 Million ≈ $135.19 Million |
0.282x | -55.92% |
| 2020-12-31 | CN¥972.66 Million ≈ $142.33 Million |
CN¥622.72 Million ≈ $91.12 Million |
0.640x | +105.08% |
| 2019-12-31 | CN¥293.20 Million ≈ $42.90 Million |
CN¥91.53 Million ≈ $13.39 Million |
0.312x | +261.00% |
| 2018-12-31 | CN¥215.10 Million ≈ $31.48 Million |
CN¥18.60 Million ≈ $2.72 Million |
0.086x | -40.04% |
| 2017-12-31 | CN¥138.61 Million ≈ $20.28 Million |
CN¥19.99 Million ≈ $2.93 Million |
0.144x | -41.34% |
| 2016-12-31 | CN¥27.32 Million ≈ $4.00 Million |
CN¥6.72 Million ≈ $982.82K |
0.246x | -- |
About Hangzhou Alltest Biotech Co. Ltd. A
Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; flu… Read more